ClinicalThought™
Interact with experts and peers.

Recent Posts

10 of 60 Shown
  • Targeted Therapy for Indolent Lymphomas: Where We Are and Where We Are Heading

    Steven M. Horwitz MD - 5/26/2015
    How do recent advances in targeted therapies affect patients with less common forms of indolent non-Hodgkin’s lymphoma?
  • The CLL Treatment Revolution

    Jeff P. Sharman MD - 5/26/2015
    Expert insight on treatment selection for patients with relapsed chronic lymphocytic leukemia.
  • A CML Patient With Elevated BCR-ABL at 3 Months: To Switch or Not to Switch?

    Elias Jabbour MD - 4/27/2015
    Knowing when to switch treatment based on BCR-ABL levels is key to effective CML therapy.
  • Utility of Kinase Inhibitors in the Management of Relapsed CLL

    Farrukh Awan MD, MS - 4/27/2015 1 comment / Last Comment: 5/19/2015
    Have you integrated recently approved kinase inhibitors into your management strategies for patients with relapsed CLL?
  • Acute Myeloid Leukemia: Will Understanding the Biology Lead to Better Outcomes?

    Farhad Ravandi MD - 3/26/2015 1 comment / Last Comment: 4/7/2015
    New therapeutic targets are beginning to offer improved strategies for AML treatment.
  • Ibrutinib and the Management of Patients With del(17p) CLL

    Farrukh Awan MD, MS - 3/23/2015 1 comment / Last Comment: 4/7/2015
    How ibrutinib earned its place among first-line treatment options for patients with CLL and del(17p)
  • How I Treat My Patients With CLL Who Are Fit or Otherwise Healthy

    Jeff P. Sharman MD - 3/11/2015 2 comments / Last Comment: 3/24/2015
    Chemotherapy or novel agents for initial treatment of CLL? Learn how to best apply new molecular markers to individualize treatment for your patients who are fit or otherwise healthy.
  • Beyond R-CHOP-21: Risk-Adapted Therapy for DLBCL

    Andrew D. Zelenetz MD, PhD - 3/10/2015 1 comment / Last Comment: 3/17/2015
    An overview of investigational strategies seeking to improve outcomes with R-CHOP in DLBCL.
  • New Options for Patients With Relapsed/Refractory ALL

    Elias Jabbour MD - 2/20/2015 1 comment / Last Comment: 2/21/2015
    The use of novel targeted therapies and immunotherapies is showing promise in ALL. These agents are achieving great responses not only in pediatric patients but also in adult patients with relapsed/refractory ALL.
  • Is Immune Modulation the Future of Therapy in Follicular Lymphoma?

    Andrew D. Zelenetz MD, PhD - 2/11/2015 2 comments / Last Comment: 4/7/2015
    Insights on the utility of immunotherapy in follicular lymphoma from recent clinical trials.
10 of 60 Shown
Show 10 More
Loading...